Drug Profile
MTL 401
Alternative Names: MTL-401Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Morvus Technology
- Class Antineoplastics
- Mechanism of Action Prodrug activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Solid-tumours in United Kingdom
- 13 Jul 2016 Early research in Solid tumours in United Kingdom (unspecified route)